Table of Content

1 Tumor Necrosis Factor Inhibitors Drug Market Overview
1.1 Tumor Necrosis Factor Inhibitors Drug Product Overview
1.2 Tumor Necrosis Factor Inhibitors Drug Market Segment by Type
1.2.1 Cimzia (Certolizumab Pegol)
1.2.2 Enbrel (Etanercept)
1.2.3 Humira ( Adalimumab)
1.2.4 Otezla (Apremilast)
1.2.5 Remicade (Infliximab)
1.2.6 Simponi (Golimumab)
1.3 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Type
1.3.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2018-2024)
2 Global Tumor Necrosis Factor Inhibitors Drug Market Competition by Company
2.1 Global Top Players by Tumor Necrosis Factor Inhibitors Drug Sales (2018-2024)
2.2 Global Top Players by Tumor Necrosis Factor Inhibitors Drug Revenue (2018-2024)
2.3 Global Top Players by Tumor Necrosis Factor Inhibitors Drug Price (2018-2024)
2.4 Global Top Manufacturers Tumor Necrosis Factor Inhibitors Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Tumor Necrosis Factor Inhibitors Drug Market Competitive Situation and Trends
2.5.1 Tumor Necrosis Factor Inhibitors Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Tumor Necrosis Factor Inhibitors Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitors Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Tumor Necrosis Factor Inhibitors Drug Market
2.8 Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Tumor Necrosis Factor Inhibitors Drug Status and Outlook by Region
3.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Size by Region
3.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales in Value by Region (2018-2024)
3.2.3 Global Tumor Necrosis Factor Inhibitors Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Region
3.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Tumor Necrosis Factor Inhibitors Drug Sales in Value by Region (2024-2034)
3.3.3 Global Tumor Necrosis Factor Inhibitors Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Tumor Necrosis Factor Inhibitors Drug by Application
4.1 Tumor Necrosis Factor Inhibitors Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Application
4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2018-2024)
5 North America Tumor Necrosis Factor Inhibitors Drug by Country
5.1 North America Tumor Necrosis Factor Inhibitors Drug Historic Market Size by Country
5.1.1 North America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2018-2024)
5.2 North America Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Country
5.2.1 North America Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2024-2034)
6 Europe Tumor Necrosis Factor Inhibitors Drug by Country
6.1 Europe Tumor Necrosis Factor Inhibitors Drug Historic Market Size by Country
6.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2018-2024)
6.2 Europe Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Country
6.2.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug by Region
7.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Historic Market Size by Region
7.1.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales in Value by Region (2024-2034)
8 Latin America Tumor Necrosis Factor Inhibitors Drug by Country
8.1 Latin America Tumor Necrosis Factor Inhibitors Drug Historic Market Size by Country
8.1.1 Latin America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2018-2024)
8.2 Latin America Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Country
8.2.1 Latin America Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug by Country
9.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Historic Market Size by Country
9.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Apogenix
10.1.1 Apogenix Company Information
10.1.2 Apogenix Introduction and Business Overview
10.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Products Offered
10.1.5 Apogenix Recent Development
10.2 AryoGen Biopharma
10.2.1 AryoGen Biopharma Company Information
10.2.2 AryoGen Biopharma Introduction and Business Overview
10.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Products Offered
10.2.5 AryoGen Biopharma Recent Development
10.3 Bionovis
10.3.1 Bionovis Company Information
10.3.2 Bionovis Introduction and Business Overview
10.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Products Offered
10.3.5 Bionovis Recent Development
10.4 CASI Pharmaceuticals
10.4.1 CASI Pharmaceuticals Company Information
10.4.2 CASI Pharmaceuticals Introduction and Business Overview
10.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
10.4.5 CASI Pharmaceuticals Recent Development
10.5 Celltrion
10.5.1 Celltrion Company Information
10.5.2 Celltrion Introduction and Business Overview
10.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Products Offered
10.5.5 Celltrion Recent Development
10.6 Celgene Corporation
10.6.1 Celgene Corporation Company Information
10.6.2 Celgene Corporation Introduction and Business Overview
10.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Products Offered
10.6.5 Celgene Corporation Recent Development
10.7 Delenex Therapeutics
10.7.1 Delenex Therapeutics Company Information
10.7.2 Delenex Therapeutics Introduction and Business Overview
10.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Products Offered
10.7.5 Delenex Therapeutics Recent Development
10.8 Dexa Medica
10.8.1 Dexa Medica Company Information
10.8.2 Dexa Medica Introduction and Business Overview
10.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Products Offered
10.8.5 Dexa Medica Recent Development
10.9 EPIRUS Biopharmaceuticals
10.9.1 EPIRUS Biopharmaceuticals Company Information
10.9.2 EPIRUS Biopharmaceuticals Introduction and Business Overview
10.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
10.9.5 EPIRUS Biopharmaceuticals Recent Development
10.10 Janssen Biotech
10.10.1 Janssen Biotech Company Information
10.10.2 Janssen Biotech Introduction and Business Overview
10.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Products Offered
10.10.5 Janssen Biotech Recent Development
10.11 GlaxoSmithKline
10.11.1 GlaxoSmithKline Company Information
10.11.2 GlaxoSmithKline Introduction and Business Overview
10.11.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Products Offered
10.11.5 GlaxoSmithKline Recent Development
10.12 HanAll Biopharma
10.12.1 HanAll Biopharma Company Information
10.12.2 HanAll Biopharma Introduction and Business Overview
10.12.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Products Offered
10.12.5 HanAll Biopharma Recent Development
10.13 Intas Pharmaceuticals
10.13.1 Intas Pharmaceuticals Company Information
10.13.2 Intas Pharmaceuticals Introduction and Business Overview
10.13.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
10.13.5 Intas Pharmaceuticals Recent Development
10.14 LEO Pharma
10.14.1 LEO Pharma Company Information
10.14.2 LEO Pharma Introduction and Business Overview
10.14.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.14.4 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Products Offered
10.14.5 LEO Pharma Recent Development
10.15 LG Life Sciences
10.15.1 LG Life Sciences Company Information
10.15.2 LG Life Sciences Introduction and Business Overview
10.15.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.15.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Products Offered
10.15.5 LG Life Sciences Recent Development
10.16 MedImmune
10.16.1 MedImmune Company Information
10.16.2 MedImmune Introduction and Business Overview
10.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.16.4 MedImmune Tumor Necrosis Factor Inhibitors Drug Products Offered
10.16.5 MedImmune Recent Development
10.17 Momenta Pharmaceuticals
10.17.1 Momenta Pharmaceuticals Company Information
10.17.2 Momenta Pharmaceuticals Introduction and Business Overview
10.17.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.17.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
10.17.5 Momenta Pharmaceuticals Recent Development
10.18 Novartis
10.18.1 Novartis Company Information
10.18.2 Novartis Introduction and Business Overview
10.18.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.18.4 Novartis Tumor Necrosis Factor Inhibitors Drug Products Offered
10.18.5 Novartis Recent Development
10.19 PROBIOMED
10.19.1 PROBIOMED Company Information
10.19.2 PROBIOMED Introduction and Business Overview
10.19.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.19.4 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Products Offered
10.19.5 PROBIOMED Recent Development
10.20 Reliance Life Sciences
10.20.1 Reliance Life Sciences Company Information
10.20.2 Reliance Life Sciences Introduction and Business Overview
10.20.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.20.4 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Products Offered
10.20.5 Reliance Life Sciences Recent Development
10.21 Sandoz
10.21.1 Sandoz Company Information
10.21.2 Sandoz Introduction and Business Overview
10.21.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.21.4 Sandoz Tumor Necrosis Factor Inhibitors Drug Products Offered
10.21.5 Sandoz Recent Development
10.22 Samsung Bioepis
10.22.1 Samsung Bioepis Company Information
10.22.2 Samsung Bioepis Introduction and Business Overview
10.22.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.22.4 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Products Offered
10.22.5 Samsung Bioepis Recent Development
10.23 Sanofi-Aventis
10.23.1 Sanofi-Aventis Company Information
10.23.2 Sanofi-Aventis Introduction and Business Overview
10.23.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.23.4 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Products Offered
10.23.5 Sanofi-Aventis Recent Development
10.24 Shanghai CP Guojian Pharmaceutical
10.24.1 Shanghai CP Guojian Pharmaceutical Company Information
10.24.2 Shanghai CP Guojian Pharmaceutical Introduction and Business Overview
10.24.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.24.4 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Products Offered
10.24.5 Shanghai CP Guojian Pharmaceutical Recent Development
10.25 Shanghai Pharmaceuticals
10.25.1 Shanghai Pharmaceuticals Company Information
10.25.2 Shanghai Pharmaceuticals Introduction and Business Overview
10.25.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.25.4 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
10.25.5 Shanghai Pharmaceuticals Recent Development
10.26 Simcere Pharmaceutical
10.26.1 Simcere Pharmaceutical Company Information
10.26.2 Simcere Pharmaceutical Introduction and Business Overview
10.26.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.26.4 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Products Offered
10.26.5 Simcere Pharmaceutical Recent Development
10.27 Toyama Chemical
10.27.1 Toyama Chemical Company Information
10.27.2 Toyama Chemical Introduction and Business Overview
10.27.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.27.4 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Products Offered
10.27.5 Toyama Chemical Recent Development
10.28 Tsumura
10.28.1 Tsumura Company Information
10.28.2 Tsumura Introduction and Business Overview
10.28.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.28.4 Tsumura Tumor Necrosis Factor Inhibitors Drug Products Offered
10.28.5 Tsumura Recent Development
10.29 UCB
10.29.1 UCB Company Information
10.29.2 UCB Introduction and Business Overview
10.29.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.29.4 UCB Tumor Necrosis Factor Inhibitors Drug Products Offered
10.29.5 UCB Recent Development
10.30 Zydus Cadila
10.30.1 Zydus Cadila Company Information
10.30.2 Zydus Cadila Introduction and Business Overview
10.30.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2018-2024)
10.30.4 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Products Offered
10.30.5 Zydus Cadila Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis
11.4 Tumor Necrosis Factor Inhibitors Drug Market Dynamics
11.4.1 Tumor Necrosis Factor Inhibitors Drug Industry Trends
11.4.2 Tumor Necrosis Factor Inhibitors Drug Market Drivers
11.4.3 Tumor Necrosis Factor Inhibitors Drug Market Challenges
11.4.4 Tumor Necrosis Factor Inhibitors Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Tumor Necrosis Factor Inhibitors Drug Distributors
12.3 Tumor Necrosis Factor Inhibitors Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Cimzia (Certolizumab Pegol)
Table 2. Major Company of Enbrel (Etanercept)
Table 3. Major Company of Humira ( Adalimumab)
Table 4. Major Company of Otezla (Apremilast)
Table 5. Major Company of Remicade (Infliximab)
Table 6. Major Company of Simponi (Golimumab)
Table 7. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (K Pcs)
Table 9. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type (2018-2024)
Table 10. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (US& Million)
Table 11. Global Tumor Necrosis Factor Inhibitors Drug Market Share in Value by Type (2018-2024)
Table 12. Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2018-2024) & (USD/Pcs)
Table 13. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2024-2034) & (K Pcs)
Table 14. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type (2024-2034)
Table 15. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2024-2034) & (US$ Million)
Table 16. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type (2024-2034)
Table 17. Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2024-2034) & (USD/Pcs)
Table 18. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (K Pcs)
Table 19. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Europe Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Latin America Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Type (2018-2024)
Table 27. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Global Tumor Necrosis Factor Inhibitors Drug Sales by Company (2018-2024) & (K Pcs)
Table 29. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Company (2018-2024)
Table 30. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2018-2024) & (US$ Million)
Table 31. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Company (2018-2024)
Table 32. Global Market Tumor Necrosis Factor Inhibitors Drug Price by Company (2018-2024) & (USD/Pcs)
Table 33. Global Tumor Necrosis Factor Inhibitors Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 34. Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitors Drug as of 2022)
Table 36. Date of Key Manufacturers Enter into Tumor Necrosis Factor Inhibitors Drug Market
Table 37. Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Tumor Necrosis Factor Inhibitors Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 40. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2018-2024) & (K Pcs)
Table 41. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Region (2018-2024)
Table 42. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2018-2024) & (US$ Million)
Table 43. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Region (2018-2024)
Table 44. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 45. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2024-2034) & (K Pcs)
Table 46. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Region (2024-2034)
Table 47. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2024-2034) & (US$ Million)
Table 48. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Region (2024-2034)
Table 49. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 50. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 51. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) & (K Pcs)
Table 52. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application (2018-2024)
Table 53. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) & (US$ Million)
Table 54. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application (2018-2024)
Table 55. Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2018-2024) & (USD/Pcs)
Table 56. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2024-2034) & (K Pcs)
Table 57. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application (2024-2034)
Table 58. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2024-2034) & (US$ Million)
Table 59. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application (2024-2034)
Table 60. Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2024-2034) & (USD/Pcs)
Table 61. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) (K Pcs)
Table 62. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) (K Pcs)
Table 70. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (K Pcs)
Table 72. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2018-2024)
Table 73. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (US$ Million)
Table 74. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2018-2024)
Table 75. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (K Pcs)
Table 76. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2024-2034)
Table 77. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (US$ Million)
Table 78. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2024-2034)
Table 79. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (K Pcs)
Table 80. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2018-2024)
Table 81. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (US$ Million)
Table 82. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2018-2024)
Table 83. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (K Pcs)
Table 84. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2024-2034)
Table 85. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (US$ Million)
Table 86. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2024-2034)
Table 87. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2018-2024) & (K Pcs)
Table 88. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Region (2018-2024)
Table 89. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Region (2018-2024)
Table 91. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2024-2034) & (K Pcs)
Table 92. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Region (2024-2034)
Table 93. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2024-2034) & (US$ Million)
Table 94. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Region (2024-2034)
Table 95. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (K Pcs)
Table 96. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2018-2024)
Table 97. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (US$ Million)
Table 98. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2018-2024)
Table 99. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (K Pcs)
Table 100. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2024-2034)
Table 101. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (US$ Million)
Table 102. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2024-2034)
Table 103. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (K Pcs)
Table 104. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2018-2024)
Table 105. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2018-2024) & (US$ Million)
Table 106. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2018-2024)
Table 107. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (K Pcs)
Table 108. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Country (2024-2034)
Table 109. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2024-2034) & (US$ Million)
Table 110. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Country (2024-2034)
Table 111. Apogenix Company Information
Table 112. Apogenix Introduction and Business Overview
Table 113. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 114. Apogenix Tumor Necrosis Factor Inhibitors Drug Product
Table 115. Apogenix Recent Development
Table 116. AryoGen Biopharma Company Information
Table 117. AryoGen Biopharma Introduction and Business Overview
Table 118. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 119. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product
Table 120. AryoGen Biopharma Recent Development
Table 121. Bionovis Company Information
Table 122. Bionovis Introduction and Business Overview
Table 123. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 124. Bionovis Tumor Necrosis Factor Inhibitors Drug Product
Table 125. Bionovis Recent Development
Table 126. CASI Pharmaceuticals Company Information
Table 127. CASI Pharmaceuticals Introduction and Business Overview
Table 128. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 129. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 130. CASI Pharmaceuticals Recent Development
Table 131. Celltrion Company Information
Table 132. Celltrion Introduction and Business Overview
Table 133. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 134. Celltrion Tumor Necrosis Factor Inhibitors Drug Product
Table 135. Celltrion Recent Development
Table 136. Celgene Corporation Company Information
Table 137. Celgene Corporation Introduction and Business Overview
Table 138. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 139. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product
Table 140. Celgene Corporation Recent Development
Table 141. Delenex Therapeutics Company Information
Table 142. Delenex Therapeutics Introduction and Business Overview
Table 143. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 144. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product
Table 145. Delenex Therapeutics Recent Development
Table 146. Dexa Medica Company Information
Table 147. Dexa Medica Introduction and Business Overview
Table 148. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 149. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product
Table 150. Dexa Medica Recent Development
Table 151. EPIRUS Biopharmaceuticals Company Information
Table 152. EPIRUS Biopharmaceuticals Introduction and Business Overview
Table 153. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 154. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 155. EPIRUS Biopharmaceuticals Recent Development
Table 156. Janssen Biotech Company Information
Table 157. Janssen Biotech Introduction and Business Overview
Table 158. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 159. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product
Table 160. Janssen Biotech Recent Development
Table 161. GlaxoSmithKline Company Information
Table 162. GlaxoSmithKline Introduction and Business Overview
Table 163. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 164. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product
Table 165. GlaxoSmithKline Recent Development
Table 166. HanAll Biopharma Company Information
Table 167. HanAll Biopharma Introduction and Business Overview
Table 168. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 169. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product
Table 170. HanAll Biopharma Recent Development
Table 171. Intas Pharmaceuticals Company Information
Table 172. Intas Pharmaceuticals Introduction and Business Overview
Table 173. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 174. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 175. Intas Pharmaceuticals Recent Development
Table 176. LEO Pharma Company Information
Table 177. LEO Pharma Introduction and Business Overview
Table 178. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 179. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product
Table 180. LEO Pharma Recent Development
Table 181. LG Life Sciences Company Information
Table 182. LG Life Sciences Introduction and Business Overview
Table 183. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 184. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product
Table 185. LG Life Sciences Recent Development
Table 186. MedImmune Company Information
Table 187. MedImmune Introduction and Business Overview
Table 188. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 189. MedImmune Tumor Necrosis Factor Inhibitors Drug Product
Table 190. MedImmune Recent Development
Table 191. Momenta Pharmaceuticals Company Information
Table 192. Momenta Pharmaceuticals Introduction and Business Overview
Table 193. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 194. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 195. Momenta Pharmaceuticals Recent Development
Table 196. Novartis Company Information
Table 197. Novartis Introduction and Business Overview
Table 198. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 199. Novartis Tumor Necrosis Factor Inhibitors Drug Product
Table 200. Novartis Recent Development
Table 201. PROBIOMED Company Information
Table 202. PROBIOMED Introduction and Business Overview
Table 203. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 204. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product
Table 205. PROBIOMED Recent Development
Table 206. Reliance Life Sciences Company Information
Table 207. Reliance Life Sciences Introduction and Business Overview
Table 208. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 209. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product
Table 210. Reliance Life Sciences Recent Development
Table 211. Sandoz Company Information
Table 212. Sandoz Introduction and Business Overview
Table 213. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 214. Sandoz Tumor Necrosis Factor Inhibitors Drug Product
Table 215. Sandoz Recent Development
Table 216. Samsung Bioepis Company Information
Table 217. Samsung Bioepis Introduction and Business Overview
Table 218. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 219. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product
Table 220. Samsung Bioepis Recent Development
Table 221. Sanofi-Aventis Company Information
Table 222. Sanofi-Aventis Introduction and Business Overview
Table 223. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 224. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product
Table 225. Sanofi-Aventis Recent Development
Table 226. Shanghai CP Guojian Pharmaceutical Company Information
Table 227. Shanghai CP Guojian Pharmaceutical Introduction and Business Overview
Table 228. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 229. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product
Table 230. Shanghai CP Guojian Pharmaceutical Recent Development
Table 231. Shanghai Pharmaceuticals Introduction and Business Overview
Table 232. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 233. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 234. Shanghai Pharmaceuticals Recent Development
Table 235. Shanghai Pharmaceuticals Company Information
Table 236. Simcere Pharmaceutical Company Information
Table 237. Simcere Pharmaceutical Introduction and Business Overview
Table 238. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 239. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product
Table 240. Simcere Pharmaceutical Recent Development
Table 241. Toyama Chemical Company Information
Table 242. Toyama Chemical Introduction and Business Overview
Table 243. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 244. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product
Table 245. Toyama Chemical Recent Development
Table 246. Tsumura Company Information
Table 247. Tsumura Introduction and Business Overview
Table 248. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 249. Tsumura Tumor Necrosis Factor Inhibitors Drug Product
Table 250. Tsumura Recent Development
Table 251. UCB Company Information
Table 252. UCB Introduction and Business Overview
Table 253. UCB Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 254. UCB Tumor Necrosis Factor Inhibitors Drug Product
Table 255. UCB Recent Development
Table 256. Zydus Cadila Company Information
Table 257. Zydus Cadila Introduction and Business Overview
Table 258. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 259. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product
Table 260. Zydus Cadila Recent Development
Table 261. Key Raw Materials Lists
Table 262. Raw Materials Key Suppliers Lists
Table 263. Tumor Necrosis Factor Inhibitors Drug Market Trends
Table 264. Tumor Necrosis Factor Inhibitors Drug Market Drivers
Table 265. Tumor Necrosis Factor Inhibitors Drug Market Challenges
Table 266. Tumor Necrosis Factor Inhibitors Drug Market Restraints
Table 267. Tumor Necrosis Factor Inhibitors Drug Distributors List
Table 268. Tumor Necrosis Factor Inhibitors Drug Downstream Customers
Table 269. Research Programs/Design for This Report
Table 270. Key Data Information from Secondary Sources
Table 271. Key Data Information from Primary Sources
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Drug Product Picture
Figure 2. Global Tumor Necrosis Factor Inhibitors Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Tumor Necrosis Factor Inhibitors Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Tumor Necrosis Factor Inhibitors Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Cimzia (Certolizumab Pegol)
Figure 6. Global Cimzia (Certolizumab Pegol) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Enbrel (Etanercept)
Figure 8. Global Enbrel (Etanercept) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Humira ( Adalimumab)
Figure 10. Global Humira ( Adalimumab) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Otezla (Apremilast)
Figure 12. Global Otezla (Apremilast) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of Remicade (Infliximab)
Figure 14. Global Remicade (Infliximab) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Simponi (Golimumab)
Figure 16. Global Simponi (Golimumab) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2018-2034) & (US$ Million)
Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2022 & 2034
Figure 19. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2022
Figure 20. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2022
Figure 21. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2022
Figure 22. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2022
Figure 23. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2022
Figure 24. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2022
Figure 25. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2022
Figure 26. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2022
Figure 27. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2022
Figure 28. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2022
Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Tumor Necrosis Factor Inhibitors Drug Sales in 2022
Figure 30. The 5 and 10 Largest Manufacturers in the World: Market Share by Tumor Necrosis Factor Inhibitors Drug Revenue in 2022
Figure 31. Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Product Picture of Clinic
Figure 33. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Hospital
Figure 35. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Product Picture of Others
Figure 37. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2018-2034) & (US$ Million)
Figure 39. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2022 & 2034
Figure 40. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2022
Figure 41. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2022
Figure 42. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2022
Figure 43. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2022
Figure 46. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Tumor Necrosis Factor Inhibitors Drug Manufacturing Cost Structure
Figure 51. Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed